ViiV ownership shifts as Pfizer sells its stake Pfizer will relinquish its stake in HIV firm ViiV in a deal valued at $2.1bn that ramps up Shionogi's interest and simplifies its share structure

#ViiV #Pfizer #ViiVHealthcare #Shionogi #HIV #GSK #strategicpartnership #jointventure #HIVtherapies #GileadSciences #HIVtreatment #antiretroviraltherapy #longeractinginjectableregimens #HIVpreexposureprophylaxis #PrEP #preexposureprophylaxis #Apretude #cabotegravir #lenacapavir
zurl.co/khJ6D

Federally Funded Clinical Trial Suggests Knowing HIV ‘Viral Load’ Doesn’t Improve Number of Patients Seeking Needed Care | Newswise According to the U.S. Centers for Disease Control and Prevention (CDC) and other sources, there are approximately 1.2 million people living with HIV in the United States, and another 1.2 to 2.2 millio...

Federally Funded Clinical Trial Suggests Knowing HIV ‘Viral Load’ Doesn’t Improve Number of Patients Seeking Needed Care
www.newswise.com/articles/fed...
#antiretroviraltherapy #HIV #JohnsHopkinsMedicine #PreExposureProphylaxis #viralloadtesting #matthewhamill #linkagetocare #yukamanabe

Gilead's twice-yearly PrEP drug is cleared by FDA Gilead has FDA approval for a twice-yearly PrEP drug, but could proposed cuts to US funding for HIV prevention programmes hinder its take-up?

#PrEP #PrEP #FDA #GileadSciences #HIV #USA #preexposureprophylaxis #PrEP #HIVpreexposureprophylaxis #Yeztugo #phase3trials #PURPOSE1 #PURPOSE2 #HIVprevention #Truvada #PrEPmarket #emtricitabinetenofoviralafenamide #PrEPusers #HIVfunding #Prep4All
pharmaphorum.com/news/gileads...

FDA Approves Twice-Yearly Lenacapavir for HIV Preexposure Prophylaxis Lenacapavir becomes the first and only twice-yearly option for HIV prevention.

FDA Approves Twice-Yearly Lenacapavir for HIV Preexposure Prophylaxis - buff.ly/1n5yD9V #clinicaltrial #clinicaltrials #hiv #preexposureprophylaxis #fda

Still from The Lion King; Simba, Pumbaa, and Timon strutting on a log. White text: HAKUNA TRUVADA MEANS NO WORRIES

#prep #preexposureprophylaxis #truvada